Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Trials
The open-label extension of the OPERA I and II randomized clinical trials assesses 10-year safety and efficacy of ocrelizumab in patients with relapsing multiple sclerosis.
